An interventional study of Rapid cardiac arrest recognition that triggers immediate priority EMS/first responder dispatch by 911 operators and Systematic bystander resuscitation instruction by 911 operators in Cardiac Arrest, sponsored by Duke University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Duke University · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 171 studies in Heart Arrest with a site in United States — 40 open to participants now, 45 under way, 2 of them phase 3. Heart Arrest · United States.
Among the 171 studies in Heart Arrest with a site in United States, this one is the 5th largest by planned enrollment of the 117 interventional ones that give a count, is one of 5 that started in 2022, is one of 67 with no phase, reaches primary completion later than 3 of the 44 other live ones, and was the 114th registered.
927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.
Browse Heart Arrest studies →40 of the 171 studies in Heart Arrest with a site in United States are open now. Recruiting first, the newest first:
Columbia University · Sites in United States, Brazil, Canada and 2 more countries
Ages 18+
University of Massachusetts, Worcester · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 1 days–17 yrs
Mayo Clinic · Sites in United States
Ages 18+
Children's Hospital of Philadelphia · Sites in United States
Ages 0 days–17 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
171 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 24 · Phase 3 12 · Phase 4 4
First in 2002; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20,000 is above the median of 100 across 519 interventional studies indexed under Heart Arrest.
Median enrollment 72 across the 117 interventional studies, 157 across the 54 observational. Of the 114 that completed or were terminated, 50 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 171 have an industry lead sponsor. The 10 most frequent:
Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.
Duke University has 2 studies filed under Heart Arrest — fewer than ten, so there is no comparison to draw.
17 of the studies in Heart Arrest with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05283850Phase 3Carol BernierSurviving PEA in Roanoke (SPEAR) Study | 2027-02 |
| NCT06109181Lexeo TherapeuticsGene Therapy for ACM Due to a PKP2 Pathogenic Variant | 2026-12 |
| NCT05893420AgileMD, Inc.A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning | 2026-12-31 |
| NCT02664831MaineHealthImmunoinflammatory Response in Post Cardiac Arrest Syndrome (PCAS) | 2027-01 |
| NCT07656259Mayo ClinicCOMPARE-VENT Feasibility Pilot Study | 2027-02-28 |
Add all 17 to your calendar (.ics) → With an account.
Among the 171 studies in Heart Arrest with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
RACE-CARS is a real-world cluster-randomized trial designed to evaluate a multifaceted community and health systems intervention aimed to improve outcomes of out-of-hospital cardiac arrest. RACE-CARS will enroll 50 counties in North Carolina that are estimated to have a total of approximately 20,000 patients with cardiac arrest over a 4-year intervention period. County "clusters" will be randomized in a 1:1 ratio to intervention versus usual care. The trial duration is 7 years, which includes a 6-month start-up (including recruitment and randomization) period, a 12-month intervention training phase, a 4-year intervention period, a 12-month follow-up for to assess quality of life in survivors of OHCA, and a 6-month close-out and data analysis period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Untreated cardiac arrests, including arrests in which resuscitation efforts are not initiated or are terminated immediately upon arrival of EMS because the patient is not a viable candidate for resuscitation due to:
Mass community CPR/AED training, optimize 911 medical dispatch, improve first responder performance
Other: Rapid cardiac arrest recognition that triggers immediate priority EMS/first responder dispatch by 911 operators · Other: Systematic bystander resuscitation instruction by 911 operators · Other: Comprehensive community training of lay people in CPR and AED use. · Other: Optimized first responder performance including earlier use of AEDs.
Usual care, continuing standard quality improvement effort
EMS first responders will recognize cardiac arrest and respond immediately, increasing time to dispatch
911 operators will be able to describe how to administer CPR over the phone.
Training of lay people regarding CPR and AED use.
First responders will recognize where AEDs are located and use them appropriately
Survival with good neurologic outcomes as measured by a CPC score of 1 or 2 at discharge
Cerebral Performance Category (CPC)
Time frame: up to 12months
Percent of patients who receive CPR from a bystander as measured by EMS report
Time frame: Baseline
Rate of Defibrillation before paramedics arrive as measured by bystander interview
Time frame: Baseline
Percent of cardiac arrest patients whose cardiac arrests are recognized by 911-dispatcher through telephone call
Time frame: Baseline
Percent of cardiac arrest patients with responders who receive CPR instructions by 911-dispatcher through telephone call
Time frame: Baseline
Survival rate as measured by medical record abstraction
Time frame: Follow-up, up to 12 months
Change in Neurologic disability as measured by Modified Rankin Score
The Modified Rankin Score is a 6 point likert scale, with 0 being "No symptoms" and 6 being "Dead"
Time frame: 3 months, 12 months
Change in Quality of life as measured by the SF-36
The SF-36 is Is a health-related quality-of-life questionnaire consisting of thirty six questions that measure eight health domains to assess physical and mental health. Physical health-related domains include General Health (GH), Physical Functioning (PF), Role Physical (RP), and Body Pain (BP).
Time frame: 3 months, 12 months
Change in Quality of life as measured by the EQ-5D-5L
The EQ-5D-5L is Quality of Life instrument measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Time frame: 3 months, 12 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2022 to primary completion in Sep 2026, 50 months.
Of 205 non-industry interventional studies with no phase under Heart Arrest, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 47. This study's 50 months is above that.
Counting every sponsor, half of 219 studies reached it within 28 months; a quarter within 10 and three quarters within 48.
Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 28, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.